参考文献

2020-10-20

1: LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK547982/ PubMed PMID: 31643315.

2: Pérez-Ruiz F, Jansen T, Tausche AK, Juárez-Campo M, Gurunath RK, Richette P. Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout. Drugs Context. 2019 May 29;8:212581. doi: 10.7573/dic.212581. eCollection 2019. Review. PubMed PMID: 31191704; PubMed Central PMCID: PMC6544139.

3: Dean L. Lesinurad Therapy and CYP2C9 Genotype. 2019 Feb 11. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A, editors. Medical Genetics Summaries [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2012-. Available from http://www.ncbi.nlm.nih.gov/books/NBK537366/ PubMed PMID: 30742400.

4: Jansen TL, Perez-Ruiz F, Tausche AK, Richette P. International position paper on the appropriate use of uricosurics with the introduction of lesinurad. Clin Rheumatol. 2018 Dec;37(12):3159-3165. doi: 10.1007/s10067-018-4306-9. Epub 2018 Sep 22. Review. PubMed PMID: 30244431.

5: Claus LW, Saseen JJ. Patient considerations in the management of gout and role of combination treatment with lesinurad. Patient Relat Outcome Meas. 2018 Jul 18;9:231-238. doi: 10.2147/PROM.S108868. eCollection 2018. Review. PubMed PMID: 30140163; PubMed Central PMCID: PMC6054769.

6: On PC. Lesinurad (Zurampic) for Gout. Am Fam Physician. 2018 Mar 15;97(6):374-375. Review. PubMed PMID: 29671542.

7: Haber SL, Fente G, Fenton SN, Walker EP, Weaver BM, Cano AJ, Vu K. Lesinurad: A Novel Agent for Management of Chronic Gout. Ann Pharmacother. 2018 Jul;52(7):690-696. doi: 10.1177/1060028018762103. Epub 2018 Feb 26. Review. PubMed PMID: 29482353.

8: Jones G, Panova E, Day R. Guideline development for the management of gout: role of combination therapy with a focus on lesinurad. Drug Des Devel Ther. 2017 Oct 24;11:3077-3081. doi: 10.2147/DDDT.S97959. eCollection 2017. Review. Erratum in: Drug Des Devel Ther. 2017 Dec 15;11:3589-3590. PubMed PMID: 29123379; PubMed Central PMCID: PMC5661481.

9: Deeks ED. Lesinurad: A Review in Hyperuricaemia of Gout. Drugs Aging. 2017 May;34(5):401-410. doi: 10.1007/s40266-017-0461-y. Review. PubMed PMID: 28425024.

10: Gupta A, Sharma PK, Misra AK, Singh S. Lesinurad: A significant advancement or just another addition to existing therapies of gout? J Pharmacol Pharmacother. 2016 Oct-Dec;7(4):155-158. doi: 10.4103/0976-500X.195897. Review. PubMed PMID: 28163535; PubMed Central PMCID: PMC5242027.

11: Lesinurad (Zurampic) for gout-associated hyperuricemia. Med Lett Drugs Ther. 2016 Nov 21;58(1508):148-150. Review. PubMed PMID: 27849193.

12: Hoy SM. Lesinurad: First Global Approval. Drugs. 2016 Mar;76(4):509-16. doi: 10.1007/s40265-016-0550-y. Review. PubMed PMID: 26861027.